| Fri, 21 Jan 2022 15:40:56: | Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold water
|
| Fri, 21 Jan 2022 13:00:49: | MD Anderson inks deal to put Chinese cancer drugs through trials, starting with a PI3K inhibitor
|
| Fri, 21 Jan 2022 11:37:02: | Kura exits FDA clinical hold after agreeing to mitigation measures, enabling resumption of blood cancer trial
|
| Thu, 20 Jan 2022 13:54:28: | CROs embracing tech to decentralize trials and speed enrollment as regulators show support 'with their feet'
|
| Thu, 20 Jan 2022 13:18:44: | Fresh from $86M series A, Metis poaches Kala CSO to support move into the clinic
|
| Thu, 20 Jan 2022 10:27:33: | Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount
|
| Wed, 19 Jan 2022 18:56:13: | Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm
|
| Wed, 19 Jan 2022 17:59:44: | Fierce JPM Week: As Novartis tries to avoid 'me-too' meds in M&A hunt, R&D chief urges biotechs to 'please reach out'
|
| Wed, 19 Jan 2022 15:09:25: | Charles River diving deeper into AI drug development in partnership with Valo Health
|
| Wed, 19 Jan 2022 11:36:27: | Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse disease
|
| Wed, 19 Jan 2022 10:42:58: | Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he began
|
| Tue, 18 Jan 2022 14:07:20: | Eli Lilly lines up metabolic pacts with Evotec, Abbisko as it awaits diabetes med nod from FDA
|
| Tue, 18 Jan 2022 13:26:53: | With $825M SPAC merger, ProKidney sets stage for phase 3 trial of kidney disease cell therapy
|
| Tue, 18 Jan 2022 12:38:25: | Fierce JPM Week: Johnson & Johnson's JLABS—Taming the beast, while letting it roam the world
|
| Tue, 18 Jan 2022 10:37:22: | Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial
|
| Fri, 14 Jan 2022 15:33:14: | 'Shots on goal' to 'deterministic' drug development: Flagship CEO, Moderna Chair Afeyan pens first annual letter
|
| Fri, 14 Jan 2022 14:49:46: | JPM 2022: Decentralized trials, broader service offerings and novel drugs key trends in the CRO space
|
| Fri, 14 Jan 2022 12:04:23: | FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish
|
| Fri, 14 Jan 2022 10:47:54: | EMA sets out plan to accelerate clinical trials, reduce administrative burden
|
| Thu, 13 Jan 2022 14:04:23: | FDA denies Denali's Takeda-partnered Alzheimer's drug from entering clinic
|
| Thu, 13 Jan 2022 13:27:33: | Sarepta, with pivotal data in sight, dumps Lysogene gene therapy
|
| Thu, 13 Jan 2022 13:25:22: | JPM22, Day 4: Galapagos plots rebound with M&A, new CEO; Gritstone hopes for new cancer biomarker; Vertex's cystic fibrosis dominance
|
| Thu, 13 Jan 2022 12:48:08: | AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targets
|
| Wed, 12 Jan 2022 13:27:49: | JPM22, Day 3: Intellia, Editas plan to double down on gene editing data in 2022; Roche launches smart glucose monitor
|
| Wed, 12 Jan 2022 13:16:49: | Sanofi makes $75M preclinical bet to join Roche, Novartis and more in congested Parkinson's field
|
